Last updated: 10 March 2023 at 8:03pm EST

Dr. Joanne Jenkins Lager M.D. Net Worth




The estimated Net Worth of Joanne Jenkins Lager is at least 762 千$ dollars as of 11 March 2022. Dr Lager owns over 3,500 units of iTeos Therapeutics stock worth over 55,965$ and over the last 4 years he sold ITOS stock worth over 0$. In addition, he makes 705,560$ as Chief Medical Officer at iTeos Therapeutics.

Dr D ITOS stock SEC Form 4 insiders trading

Dr has made over 7 trades of the iTeos Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 3,500 units of ITOS stock worth 15,050$ on 11 March 2022.

The largest trade he's ever made was exercising 28,000 units of iTeos Therapeutics stock on 18 November 2021 worth over 120,400$. On average, Dr trades about 5,600 units every 11 days since 2021. As of 11 March 2022 he still owns at least 3,500 units of iTeos Therapeutics stock.

You can see the complete history of Dr Lager stock trades at the bottom of the page.





Dr. Joanne Jenkins Lager M.D. biography

Dr. Joanne Jenkins Lager M.D. is the Chief Medical Officer at iTeos Therapeutics.

What is the salary of Dr D?

As the Chief Medical Officer of iTeos Therapeutics, the total compensation of Dr D at iTeos Therapeutics is 705,560$. There are 2 executives at iTeos Therapeutics getting paid more, with Dr. Michel Detheux having the highest compensation of 833,750$.



How old is Dr D?

Dr D is 50, he's been the Chief Medical Officer of iTeos Therapeutics since . There are 2 older and 2 younger executives at iTeos Therapeutics. The oldest executive at iTeos Therapeutics, Inc. is Dr. Michel Detheux Ph.D., 55, who is the Pres, CEO & Director.

What's Dr D's mailing address?

Joanne's mailing address filed with the SEC is 321 ARSENAL STREET, , WATERTOWN, MA, 02472.

Insiders trading at iTeos Therapeutics

Over the last 4 years, insiders at iTeos Therapeutics have traded over 196,492,023$ worth of iTeos Therapeutics stock and bought 4,975,000 units worth 95,182,800$ . The most active insiders traders include Capital Management, L.P.Ra ...Capital Management, L.P.Kol...Aaron I. Davis. On average, iTeos Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of 1,817,279$. The most recent stock trade was executed by Matthew Gall on 12 October 2023, trading 5,000 units of ITOS stock currently worth 41,850$.



What does iTeos Therapeutics do?

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.



What does iTeos Therapeutics's logo look like?

iTeos Therapeutics, Inc. logo

Complete history of Dr Lager stock trades at iTeos Therapeutics

日付
#
会社
インサイダー
取引
取引
株式 1株当たりの株価 合計金額 その後の株式数 ソース
11 Mar 2022 Joanne Jenkins Lager
Chief Medical Officer
オプション行使 3,500 4.30$ 15,050$
11 Mar 2022
3,500
11 Feb 2022 Joanne Jenkins Lager
Chief Medical Officer
オプション行使 3,500 4.30$ 15,050$
11 Feb 2022
3,500
14 Jan 2022 Joanne Jenkins Lager
Chief Medical Officer
オプション行使 3,500 4.30$ 15,050$
14 Jan 2022
3,500
3 Jan 2022 Joanne Jenkins Lager
Chief Medical Officer
オプション行使 7,000 4.30$ 30,100$
3 Jan 2022
7,000
17 Dec 2021 Joanne Jenkins Lager
Chief Medical Officer
オプション行使 7,000 4.30$ 30,100$
17 Dec 2021
7,000
10 Dec 2021 Joanne Jenkins Lager
Chief Medical Officer
オプション行使 3,500 4.30$ 15,050$
10 Dec 2021
3,500
18 Nov 2021 Joanne Jenkins Lager
Chief Medical Officer
オプション行使 28,000 4.30$ 120,400$
18 Nov 2021
28,000


iTeos Therapeutics executives and stock owners

iTeos Therapeutics executives and other stock owners filed with the SEC include: